Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: EyePoint, Inc.

Market Cap 1.1B 961M 886M 833M 1.56B 104B 1.57B 10.54B 4.09B 51.21B 4.14B 4.05B 177B P/E 2026 *
-3.73x
P/E 2027 * -4.8x
Enterprise Value 808M 704M 649M 611M 1.14B 76.17B 1.15B 7.72B 3B 37.54B 3.03B 2.97B 130B EV / Sales 2026 *
473x
EV / Sales 2027 * 16.7x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.86%
1 week+7.36%
Current month-1.18%
1 month+14.70%
3 months-1.61%
6 months-21.34%
Current year-26.55%
1 week 11.93
Extreme 11.93
14.03
1 month 11.3
Extreme 11.295
14.03
Current year 11.3
Extreme 11.295
18.87
1 year 7.94
Extreme 7.94
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 68 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 68 15/09/2016
Director/Board Member 68 10/07/2023
Chairman 77 10/09/2018
Date Insider Type Main position Quantity % Market Cap.
05-25Fiscal year

Chief Financial Officer

18,627 0.0222%
04-17Fiscal year

Chief Technology Officer

7,311 0.0088%
03-23Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+1.98%+7.36%+50.45%+94.49% 1.1B
-0.92%-5.10%+40.35%+143.79% 992B
-2.13%-3.72%+52.23%+39.80% 564B
-1.97%-3.49%+16.94%+57.39% 391B
-2.90%+0.68%+24.66%+16.53% 330B
-2.36%-3.12%+24.71%+12.95% 280B
-2.45%-2.88%+24.29%+29.93% 279B
-1.91%-0.87%-41.95%-48.26% 196B
-1.83%-5.25%+15.83%+46.76% 184B
-1.98%-2.30%+13.87%+58.26% 156B
Average -1.73%+1.31%+22.14%+45.16% 337.23B
Weighted average by Cap. -1.90%-0.49%+28.11%+63.22%

Financials

2026 *2027 *
Net sales 1.71M 1.49M 1.37M 1.29M 2.41M 161M 2.43M 16.31M 6.33M 79.28M 6.41M 6.27M 275M 51.01M 44.44M 40.97M 38.53M 72.09M 4.81B 72.6M 487M 189M 2.37B 191M 187M 8.21B
Net income -311M -271M -250M -235M -440M -29.32B -443M -2.97B -1.15B -14.45B -1.17B -1.14B -50.09B -262M -229M -211M -198M -371M -24.74B -374M -2.51B -974M -12.19B -985M -964M -42.26B
Net Debt -294M -256M -236M -222M -416M -27.74B -419M -2.81B -1.09B -13.67B -1.1B -1.08B -47.38B -248M -216M -199M -188M -351M -23.4B -353M -2.37B -921M -11.53B -932M -912M -39.96B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
18/06/26 13.40 $ +1.86% 649,164
17/06/26 13.15 $ +2.10% 1,180,462
16/06/26 12.88 $ +6.62% 1,471,638
15/06/26 12.08 $ -7.29% 1,084,002
12/06/26 13.03 $ +4.24% 1,093,547
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
13.15USD
Average target price
37.00USD
Spread / Average Target
+181.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!